Navigation Links
Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL).  A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.  Blinatumomab is the first in a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

The findings were presented on June 12, 2010 in an oral presentation (abstract # 0559) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Blinatumomab continues to demonstrate a long duration of response in heavily pre-treated non-Hodgkin's lymphoma patients," said Professor Ralph Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wuerzburg University Hospital, and the study's principal investigator. "Results of the expanded Phase 1 experience suggest that blinatumomab has the potential to alter the clinical course of disease in patients with a variety of NHL sub-types."

Phase 1 Study Design

This multi-center Phase 1 study evaluates the safety and tolerability of blinatumomab in adult patients with relapsed non-Hodgkin's lymphoma (NHL).  The key objectives of the study are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-lymphoma activity. &#
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
2. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
3. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
4. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportlinker.com announces that a new ... Acute Heart Failure Global Clinical Trials ... Acute Heart Failure Global Clinical ... GlobalData,s clinical trial report, "Acute Heart Failure Global ... the Acute Heart Failure clinical trial scenario. This ...
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... , NEW YORK , Aug. 2 ... medical membership, announced today that, effective August 1, 2010 ... Indemnity Reference Laboratory Networks.  This expansion ensures broader choices for ... on service, quality and choice, and reduces the need for ...
... FRANKLIN LAKES, N.J. , Aug. 2 BD ... global medical technology company, today announced the completion of the sale of its ... blades product platform to one of RoundTable,s portfolio companies, Aspen Surgical Products, Inc. ... On June ...
Cached Medicine Technology:Empire BlueCross BlueShield Expands Lab Networks -- Creating Broader Choice, Robust Competition and Lower Costs for Consumers 2BD Completes Sales of Ophthalmic Systems Unit and Surgical Blades Product Platform 2
(Date:9/2/2014)... 03, 2014 Recently, Top 10 ... companies and announced that JustHost ( http://www.justhost.com/track/seohosts ) ... webmasters. , “The hosting suppliers we recommend are ... competitors on hosting features, uptime and server speed ... Best SEO Hosting says. “We believe that BlueHost ...
(Date:9/2/2014)... Cloud Medical Doctor Software Corporation (Cloud-MDs) ... Practice Business Operations solutions and Billing Services for the ... solutions for all industries announced today that its CEO ... of the CME in Chicago by PRICE Futures Group ... are very proud of the recognition that our CipherLoc ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Complications are rare among ... a new study indicates. However, the researchers ... with a slightly higher risk for certain complications ... more than 18,000 breast cancer patients who had ... with breast reconstruction and were followed for 30 ...
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... 2014 Operators in the Community ... people annually, arranging care and counsel for those in ... are expected to derive $39.4 billion in revenue, which ... income. Over the five years through 2014-15, the subdivision ... 6.6%, including growth of 4.1% in 2014-15. , As ...
Breaking Medicine News(10 mins):Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Award Winning Artist Describe Why They ... May 29 Susan G. Komen for the Cure(R),s ... African-American,leaders -- each with different backgrounds and personal stories ... around the globe to help,end breast cancer forever. The ...
... 29 Kewaunee Scientific,Corporation (Nasdaq: KEQU ) ... Company,s quarterly cash dividend to eight cents per,outstanding ... in the previous,quarter, payable on June 23, 2008 ... on June 9, 2008., Kewaunee Scientific Corporation ...
... 29 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... Meeting of Stockholders Thursday, June 12, 2008 at ... Pickering Hale & Dorr, 60 State,Street, Boston, MA., ... Alseres Pharmaceuticals, Inc., Alseres Pharmaceuticals, Inc. (ALSE) ...
... to Donate One Dollar to Change Lives, CHICAGO, ... a Bite out of Hunger" during its 70th Annual,Donut ... hundreds of Donut,taggers will hit the streets during a ... World War I when volunteers handed out donuts,to troops ...
... and Purdue universities Thursday announced the creation of ... a medical research initiative that will combine the ... swiftly transform discoveries into better patient care and ... has awarded a five-year Clinical and Translational Science ...
... Cancer Center researchers have identified that a combination of ... leukemia cells previously resistant to conventional forms of therapy. ... of the bone marrow caused by a specific genetic ... of leukemia. Imatinib mesylate, or Gleevec, is a highly ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 2Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 3Health News:Susan G. Komen for the Cure(R)'s Circle of Promise Welcomes Gabrielle Union, Lalah Hathaway, Synthia SAINT JAMES as National Ambassadors 4Health News:Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting 2Health News:The Salvation Army Takes a Bite Out of Hunger 2Health News:Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: